Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
136-150 of 4049 results
Janssen’s Guselkumab found safe for treatment of psoriatic arthritis in phase 2 study
A phase 2 study assessing Janssen Research & Development’s guselkumab has shown promise in the treatment of active psoriatic arthritis.
Contract Research & Services > Clinical Trials > News
AbbVie's pan-genotypic hepatitis C test drug regimen succeeds in phase 3 trial
By PBR Staff Writer
Results from a phase 3 clinical trial evaluating AbbVie's investigational pan-genotypic HCV regimen of glecaprevir/pibrentasvir (G/P) demonstrated high SVR rates in chronic hepatitis C patients with severe chronic kidney disease.
Contract Research & Services > Clinical Trials > News
Braeburn says phase 3 trial for injectable opioid dependence treatment succeeds
By PBR Staff Writer
A phase 3 trial of weekly and monthly injections of buprenorphine (CAM2038) to treat moderate-to-severe opioid use disorder met both FDA and EMA primary endpoints of non-inferiority.
Contract Research & Services > Clinical Trials > News
Mesoblast unveils successful interim futility analysis in Phase 3 trial for aGVHD
The phase 3 trial of Mesoblast's intravenous product candidate MSC-100-IV used as front-line therapy in children with steroid-resistant acute graft versus host disease (aGVHD) had been successful in a pre-specified interim futility analysis.
Contract Research & Services > Clinical Trials > News
Corvus' CPI-444 demonstrates evidence of anti-tumor activity as single agent in advanced refractory cancer
Corvus Pharmaceuticals announced preliminary clinical safety and efficacy data from the dose-selection phase of its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s Tecentriq (atezolizumab),‎ a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1).
Contract Research & Services > Clinical Trials > News
Elcelyx unveils positive results in phase 2b study of Metformin DR in type 2 diabetes
Elcelyx Therapeutics announced today that its Phase 2b doseranging study met the primary endpoint of showing a statistically significant reduction in HbA1c at 16 weeks with Metformin Delayed Release (Metformin DR) compared with placebo in subjects with type 2 diabetes.
Contract Research & Services > Clinical Trials > News
RegeneRx enrolls first patients in phase 3 US dry eye clinical trial with RGN-259
RegeneRx Biopharmaceuticals has enrolled the first patient in a Phase 3 clinical trial (ARISE-2 trial) with RGN-259 (Thymosin beta 4), its sterile, preservative-free eye drop formulation developed for patients with dry eye syndrome, neurotrophic keratopathy (NK), besides other corneal disorders.
Contract Research & Services > Clinical Trials > News
FDA lifts partial clinical hold on Adaptimmune's study of T-cell therapy in MRCLS
By PBR Staff Writer
The US Food and Drug Administration (FDA) has removed the partial clinical hold on Adaptimmune Therapeutics’ planned study of NY ESO specific peptide enhanced affinity receptor (SPEAR) T-cell therapy in Myxoid/round cell liposarcoma (MRCLS).
Contract Research & Services > Clinical Trials > News
Seattle Genetics, Takeda complete enrollment in phase 3 trial of ADCETRIS in frontline mature T-cell lymphoma
Seattle Genetics and Takeda Pharmaceutical Company have completed patient enrollment in the ECHELON-2 clinical trial, assessing ADCETRIS (Brentuximab Vedotin) in frontline mature T-cell lymphoma.
Contract Research & Services > Clinical Trials > News
Biogen and Ionis’ spinal muscular atrophy treatment meets primary endpoint in phase 3 study
By PBR Staff Writer
Biogen and Ionis Pharmaceuticals said that Spinraza (nusinersen), an investigational treatment for spinal muscular atrophy (SMA), has met the primary endpoint in a phase 3 trial.
Contract Research & Services > Clinical Trials > News
Onxeo unveils encouraging results from preclinical studies of Livatag in pancreatic cancer
Biopharmaceutical firm Onxeo has announced encouraging results from a series of preclinical studies evaluating Livatag interest for pancreatic cancer.
Contract Research & Services > Clinical Trials > News
Sanofi Genzyme starts phase 3 trial of second-generation enzyme replacement therapy for Pompe disease
Sanofi Genzyme, the specialty care global business unit of Sanofi, has started a pivotal Phase 3 clinical trial named COMET for the investigational therapy neoGAA for Pompe Disease.
Contract Research & Services > Clinical Trials > News
Mereo BioPharma reports positive outcome of phase 1 drug interaction study with acumapimod
UK-based Mereo BioPharma Group has reported positive results of its Phase 1 drug interaction study with acumapimod, the active compound in its p38 MAP kinase inhibitor BCT-197.
Contract Research & Services > Clinical Trials > News
Aurinia unveils plans for single phase III trial for voclosporin to treat lupus nephritis
Aurinia Pharmaceuticals has unveiled its plans for a single phase III clinical trial for voclosporin in the treatment of lupus nephritis (LN).
Contract Research & Services > Clinical Trials > News
Baxter starts phase 3 trial of new therapy for acute kidney injury
By PBR Staff Writer
Baxter International has initiated a phase 3 clinical trial of an investigational drug combining a citrate anticoagulant and renal replacement solution.
Contract Research & Services > Clinical Trials > News
136-150 of 4049 results